Presentations
On November 24, CEO Jan Nilsson presented CombiGene at Aktieportföljen Live
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On November 24, CEO Jan Nilsson presented CombiGene's development during the year and plans for the future at Aktieportföljen Live. If you didn't have the opportunity to follow the...
read moreDen 20 oktober presenterade Karin Agerman, Chief Research & Development Officer på CombiGene på ATMP Swedens webinar Manufacturing of Gene Therapy Products in Sweden
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On October 20, Karin Agerman, Chief Research & Development Officer at CombiGene presented on ATMP Sweden's webinar Manufacturing of Gene Therapy Products in Sweden. Karin gave her...
read moreOn October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna
Interviews and presentations 2020 2021 2020 2019 2018 2017 2016 2015 On October 19, CEO Jan Nilsson and Chief Research & Development Officer Karin Agerman presented CombiGene at Aktiespararna's digital event. If you didn't have the opportunity to...
read moreAnalysguiden – on CombiGenes progress with CG01 (ONLY IN SWEDISH)
Aktiedagen in Stockholm – Company Presentation (ONLY IN SWEDISH)
Watch Jan Nilsson, CEO at CombiGene present the company at Stora Aktiedagen in Göteborg november 4 (ONLY IN SWEDISH)
Presentation, Aktiedagen in Lund September 17
Presentation, Aktiedagen in Stockholm, September 10
CombiGene presents at Stockholm Corporate Finance 11th Life Science Seminar on March 13, 2019
Jan Nilsson tell us about the future among other things in an interview with Finwire
Find it easy
Presscontact
» press@combigene.com
Press & financial reports
» Pressreleases (MAR) and Financial reports
News
» News
» Ingenious
» Calendar
» Videopresentations
Downloads
» Images
» Logotypes
Newsletter
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden